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Abstract
Background: The usefulness of the Total Thrombus-Formation Anal-
ysis System® (T-TAS®) for monitoring the anticoagulant effects of 
non-vitamin K oral anticoagulants (NOACs) in clinical practice has 
been poorly addressed.
Methods: NOACs (rivaroxaban and apixaban) were added to whole 
blood from healthy subjects in an in vitro study, and their effects on 
thrombus formation were evaluated by the T-TAS®. We also evaluat-
ed antithrombotic effects using ex vivo samples of whole blood from 
patients given rivaroxaban or apixaban at the respective trough and 
peak drug concentrations.
Results: T-TAS® could determine anticoagulant effects in whole 
blood treated with rivaroxaban or apixaban in vitro. The increases in 
the anticoagulant effects of rivaroxaban and apixaban from the trough 
to peak concentrations in whole blood were successfully monitored 
by the T-TAS® using ex vivo samples. The antithrombotic effects of 
rivaroxaban and apixaban (in terms of factor Xa inhibition) at the 
peak were strongly linked to those at the trough.
Conclusion: T-TAS® could be a clinically useful tool for monitoring 
the anticoagulant effects of factor Xa inhibitors, and may represent an 
accurate quantitative analysis.
Keywords: Factor Xa inhibitors; Antithrombotic capacities; Total 
Thrombus-Formation Analysis System; Trough; Peak
Introduction
Non-vitamin K oral anticoagulants (NOACs), which include 
dabigatran, rivaroxaban, apixaban and edoxaban, were devel-
oped to prevent stroke in atrial fibrillation and deep vein throm-
bosis [1]. The safety and efficacy of NOACs in these patients 
have been generally confirmed by recent clinical trials [2-5]. In 
contrast with warfarin, which has many drug and food interac-
tions, the dose regimens of NOACs are simple and NOACs 
do not require routine coagulation monitoring. However, there 
are some circumstances in which the assessment of hemostasis 
by laboratory testing could be helpful for clinicians to make 
decisions regarding patient care, such as in the presence of ma-
jor bleeding or trauma, prior to emergent surgery, suspected 
overdose or non-compliance. Although chromogenic anti-Xa 
activity has been shown to be linear over a wide range of ri-
varoxaban and apixaban levels [6, 7], the turnaround time of 
this assay is currently too long for its application in clinical set-
tings. Among common coagulant tests, the prolongation of pro-
thrombin time (PT) depends on the concentration of factor Xa 
(FXa) inhibitors and is not particularly sensitive. In addition, a 
normal PT does not necessarily exclude clinically relevant drug 
concentrations [8, 9]. To date, there has been no definitive tool 
for monitoring the anticoagulant effects of NOACs.
The Total Thrombus-Formation Analysis System® (T-
TAS®) is an automated microchip flow chamber system that 
can quantitatively analyze thrombus formation using whole 
blood. Thrombus formation in the microchip capillaries is 
evaluated under flow and static conditions to more closely re-
flect physiological function. The T-TAS® was initially devel-
oped to monitor the efficacy of anticoagulants [10]. Using the 
T-TAS®, we recently demonstrated that blood samples from 
patients who had taken NOACs showed less ex vivo fibrin-
rich thrombus formation under a constant low rate flow condi-
tion [11]. This study supported the usefulness of the T-TAS® 
for monitoring the anticoagulant effects of NOACs in clinical 
practice. However, several limitations were noted. First, the 
antithrombotic effects of NOACs were only evaluated with 
samples from patients, and a healthy control group was not 
examined. It is possible that some patient characteristics other 
than the use of an anticoagulant medication might influence 
measurements with the T-TAS®. Second, the analysis was only 
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performed with blood samples taken just before the adminis-
tration of NOACs (at trough dose levels). Thus, it was unclear 
whether the antithrombotic effects evaluated by the T-TAS® 
depended on the concentrations of NOACs. The aim of the 
present study was to resolve these limitations. In this study, 
rivaroxaban or apixaban was added in vitro to plasma from 
healthy subjects, and their effects on thrombus formation were 
evaluated by the T-TAS®. We also tested ex vivo samples from 
patients given rivaroxaban or apixaban at their trough and peak 
concentrations.
Methods
In vitro experiment with blood from healthy volunteers
For the first part of the study, we obtained whole blood samples 
from 20 healthy volunteers who had not taken any medications 
(12 males and eight females; aged 29 - 54 years). All blood 
samples were numbered in order of registration. To confirm the 
in vitro antithrombotic effects of rivaroxaban and apixaban at 
the expected clinical peak drug level, blood samples were pre-
pared with drugs as follows. Rivaroxaban and apixaban were 
obtained from Toronto Research Chemicals (Toronto, Ontario, 
Canada). Rivaroxaban and apixaban were each dissolved in 
100% dimethylsulfoxide to yield stock solutions with a con-
centration of 5 mM. Stock solutions were then diluted in blood 
samples at the time of assay (first 16 samples in the rivaroxa-
ban group and the rest of four samples in the apixaban group). 
The target final concentration of rivaroxaban in this experiment 
was 800 μM, which corresponds to the expected peak concen-
tration (Cmax-equivalent) of rivaroxaban in blood after a dose 
of 15 mg/day [12]. Similarly, blood samples were spiked with 
apixaban stock solutions. The final concentration of apixaban 
was 450 μM, which corresponded to the peak concentration of 
apixaban in blood after a dose of 10 mg/day clinically [13, 14]. 
We immediately evaluated the antithrombotic effects of these 
spiked blood samples in comparison with thrombus formation 
in control blood by the T-TAS®.
Ex vivo experiment with blood from patients who had tak-
en rivaroxaban or apixaban
In the second part of the study to compare the ex vivo an-
tithrombotic effects of a drug dose at the trough to those of a 
drug dose at the peak, whole blood samples were obtained from 
patients at two time points: before and 4 h after drug adminis-
tration. We enrolled 16 consecutive hospitalized patients who 
had atrial fibrillation and who had taken either rivaroxaban (n 
= 6) or apixaban (n = 10) daily for at least 7 days, which was 
considered to give a steady peak to trough ratio of drug con-
centrations. Patients who were receiving an antiplatelet drug 
or anticoagulant drug other than rivaroxaban or apixaban, who 
were undergoing hemodialysis for renal insufficiency, or who 
were pregnant were excluded. Six patients were prescribed ri-
varoxaban and 10 received apixaban. The dose of rivaroxaban 
was 15 mg once daily, and apixaban was administered at doses 
of 5 mg twice daily (80% of patients) and 2.5 mg twice daily 
(20%). To evaluate the effects of the drugs on thrombus for-
mation, all samples were evaluated by the T-TAS® within 1 h 
after the patient’s blood was drawn by venipuncture. We also 
evaluated the results of common coagulation tests such as the 
PT-international normalized ratio (PT-INR) and activated par-
tial thromboplastin time (APTT) at the same two time points.
Evaluation of clinical parameters
The patients’ clinical characteristics and laboratory measure-
ments, including the prevalence of hypertension (HTN), dys-
lipidemia (DL), diabetes mellitus (DM), medication use, hem-
atocrit, platelet counts and estimated glomerular filtration rate 
(eGFR), were obtained from medical records. Patients who 
had a current systolic blood pressure (SBP) ≥ 140 mm Hg and/
or diastolic blood pressure (DBP) ≥ 90 mm Hg or who were 
receiving antihypertensive therapy were considered to have 
HTN. Patients with low-density lipoprotein cholesterol (LDL-
C) ≥ 140 mg/dL, triglycerides (TG) ≥ 150 mg/dL, and/or high-
density lipoprotein cholesterol (HDL-C) < 40 mg/dL or who 
were receiving lipid-lowering therapy were considered to have 
DL. Patients with random blood glucose (BG) ≥ 200 mg or 
fasting BG ≥ 126 mg, HbA1c ≥ 6.5% or who were taking a 
glucose-lowering drug were considered to have DM. Hemato-
logical and biochemical laboratory parameters were measured 
by an auto-analyzer at Fukuoka University Hospital.
Evaluation of thrombogenicity under flow by the T-TAS®
Thrombus formation under flow conditions was evaluated by 
the T-TAS® (Fujimori Kogyo, Kanagawa, Japan). The T-TAS® 
is an automated microchip-based flow chamber system that 
analyzes thrombus formation using two types of single-use 
microchips, as previously described in detail [11]. Briefly, the 
capillary of the platelet chip (PL-chip) is coated with type I 
collagen; platelets from blood samples adhere and aggregate 
inside the microchip under constant flow conditions. This chip 
is designed to measure primary hemostasis and it is used for 
the quantitative evaluation of platelet-specific thrombus for-
mation. The atheroma chip (AR-chip) is coated with type I col-
lagen and tissue thromboplastin and it is designed to measure 
cumulatively primary and secondary hemostasis. Inside the 
AR-chip, platelets and the coagulant system are simultane-
ously activated, which leads to the formation of a fibrin-rich 
thrombus. These thrombus-forming processes are analyzed by 
monitoring the changes in internal pressure of the chips. In 
this study, samples were collected into plastic tubes either con-
taining 3.2% sodium citrate (for AR-chip analysis) or 25 μg/
mL hirudin-containing tubes (for PL-chip analysis). Samples 
were allowed to rest for 1 h after collection, and then loaded 
in microchips under constant flow rates of 18 and 10 μL/min 
for the PL-chip and AR-chip, respectively. We analyzed sev-
eral parameters for each sample. T10 was the time at which the 
flow pressure increased by 10 kPa from the baseline due to 
partial occlusion of the capillary, and represented the onset of 
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thrombus formation. T60 and T80 were the times at which the 
flow pressure increased by 60 and 80 kPa from baseline for 
the PL-chip and AR chip, respectively. T60 and T80 represented 
near-occlusion of the capillaries. The area under the flow pres-
sure curve (AUC) was computed to assess thrombogenicity 
inside the microchips. AR-AUC represented the area under the 
flow pressure curve for 30 min after the start of perfusion for 
the AR-chip, and PL-AUC represented the area under the flow 
pressure curve for 10 min after the start of perfusion for the 
PL-chip. If a thrombus forms in the capillaries of a microchip 
early, the internal pressure should rise quickly and the value of 
AUC should increase.
This study was conducted according to a protocol ap-
proved by the Independent Review Board (IRB) of Fukuoka 
University Hospital (Fukuoka University Hospital IRB: #14-
4-04) and registered under UMIN000017228. All subjects 
gave their written informed consent to participate.
Statistical analysis
The statistical analysis was performed using JMP software, 
version 12 (SAS Institute, Cary, NC, USA). Values are pre-
sented as percentages, means and standard deviation (SD). 
Categorical and continuous variables were compared between 
two groups by a Chi-square analysis and unpaired t-test, re-
spectively. For a correlation analysis, the Spearman rank corre-
lation coefficient was used. A value of P < 0.05 was considered 
significant.
Results
In vitro antithrombotic effects of rivaroxaban and apixa-
ban in blood from healthy volunteers
Whole blood samples from healthy volunteers were analyzed 
for thrombus formation by the T-TAS® with or without drug 
application. In vitro, rivaroxaban and apixaban significantly 
suppressed fibrin-rich thrombus formation under flow condi-
tions, whereas these FXa inhibitors did not reduce the rate of 
platelet thrombus formation (Fig. 1 and Table 1). With regard 
to AR-chips, rivaroxaban at the estimated clinical peak dose 
(800 nM, n = 16) significantly suppressed thrombus forma-
tion compared to that in control blood samples, as indicated 
by a lower AR-AUC and prolonged AR-T10 and AR-T80 (AR-
AUC for rivaroxaban; 1,605 ± 176 to 831 ± 329 arbitrary 
units (AU)). Apixaban at a concentration of 450 nM (n = 4) 
inhibited thrombus formation on AR-chips in a similar fash-
ion (AR-AUC for apixaban; 1,699 ± 42 to 955 ± 141 AU). 
In contrast, neither rivaroxaban nor apixaban supplementation 
affected any of the parameters using PL-chips, including PL-
AUC, PL-T10 and PL-T60 (Fig. 1 and Table 1). Taken together, 
these results indicated that in vitro rivaroxaban and apixaban 
suppressed the coagulant system, but did not affect the func-
tion of platelets.
Baseline patient characteristics
We next tested ex vivo thrombus formation by the T-TAS® us-
ing whole blood from patients who had been regularly receiv-
ing either rivaroxaban or apixaban. The patient characteristics 
are shown in Table 2. The apixaban group showed a signifi-
cantly lower percentage (%) of males and a higher prevalence 
of DL. There were no significant differences in the other base-
line characteristics between the rivaroxaban and apixaban 
Table 1.  Changes in T-TAS® Parameters of In Vitro Experi-
ments in the Rivaroxaban and Apixaban
Rivaroxaban (n = 16) Apixaban (n = 4)
Control Spiked Control Spiked
AR-T10 (min) 7.9 ± 2.2 16.1 ± 4.5* 6.7 ± 0.2 14.0 ± 1.3*
AR-T80 (min) 12.4 ± 2.4 22.6 ± 3.2* 11.4 ± 1.1 22.6 ± 2.2*
PL-T10 (min) 2.3 ± 0.7 2.9 ± 0.7 2.2 ± 1.1 2.8 ± 0.7
PL-T60 (min) 6.0 ± 1.7 6.6 ± 1.3 6.2 ± 2.6 6.2 ± 1.5
Continuous variables are expressed as mean ± SD. *P < 0.05 vs. con-
trol.
Figure 1. In vitro antithrombotic effects (AR-AUC (a) and PL-AUC (b)) 
in the absence of (control) or presence of (spiked) rivaroxaban and 
apixaban in blood from healthy volunteers using AR-chips and PL-
chips. *P < 0.05 vs. control. 
Articles © The authors   |   Journal compilation © J Clin Med Res and Elmer Press Inc™   |   www.jocmr.org902
Effects of Rivaroxaban and Apixaban J Clin Med Res. 2016;8(12):899-907
groups.
Antithrombotic effects at the trough and peak concentra-
tions in blood from patients
At the trough, AR-AUC in the rivaroxaban group was signif-
icantly higher than that in the apixaban group (1,554 ± 133 
vs. 1,193 ± 217 AU, respectively, Fig. 2a). In the rivaroxaban 
group, the capacity to delay capillary occlusion in AR-chips 
was significantly enhanced at peak drug levels compared to 
the trough. AR-AUC was decreased by 23% from trough to 
peak, and both AR-T10 and AR-T80 were prolonged by 33% 
(Table 3). Similarly, blood samples collected 4 h after the ad-
ministration of apixaban had AR-AUC levels 22% lower than 
those at baseline. AR-T10 and AR-T80 values in the apixaban 
group also increased by 29% and 20% from the trough to peak, 
respectively. On the other hand, PL-AUC levels at the trough 
were similar in the rivaroxaban and apixaban groups (322 ± 79 
vs. 252 ± 73 AU, respectively, P = 0.13, Fig. 2b). Moreover, 
there were no differences in platelet thrombus formation, as 
reflected by PL-T10, PL-T60 and PL-AUC, between the trough 
and peak for both groups.
Correlation analysis between AR-AUC and the results of 
common coagulant tests in all patients
Common coagulation tests (PT-INR and APTT) were per-
formed at the trough and peak time points. At both the trough 
and peak, there were no significant differences in PT-INR or 
APTT between the rivaroxaban and apixaban groups (Table 
3). PT and APTT were not influenced by the dosing schedule 
of rivaroxaban or apixaban, and their levels were within the 
normal range even at the peak drug concentrations. We next 
performed a correlational analysis to clarify the associations 
between these common coagulant tests and the anticoagulant 
parameter (AR-AUC) obtained by the T-TAS. PT-INR in all 
patients was not correlated with AR-AUC at each time point 
(Fig. 3a, b). Similarly, no correlations were found between 
APTT and AR-AUC (Fig. 3c, d).
Associations of the T-TAS parameters at the trough and 
peak
Figure 4 shows the results of a correlational analysis for the 
T-TAS parameters measured with samples from all patients 
at the trough and peak time points. There was a significantly 
high correlation between AR-AUC at the trough and AR-AUC 
at the peak (r = 0.79, P = 0.001, Fig. 4a). The other throm-
bogenicity parameters obtained from the AR-chip analysis, 
including AR-T10 and AR-T80, showed an equally strong cor-
relation between the trough and peak (r = 0.72 and r = 0.81, 
respectively, Fig. 4b, c).
T-TAS parameters and complete blood count tests
Blood constituents can influence thrombus formation via the 
Table 2.  Patient Characteristics in All Patients, the Rivaroxaban and Apixaban Groups
All Rivaroxaban Apixaban
N 16 6 10
Age, years 68 ± 9 67 ± 10 69 ± 9
Male, IN/TN (%) 10/16 (63) 5/6 (83) 5/10 (50)†
BMI, kg/m2 24 ± 3 24 ± 4 23 ± 4
HTN, IN/TN (%) 12/16 (75) 4/6 (67) 8/10 (80)
DL, IN/TN (%) 10/16 (63) 2/6 (33) 8/10 (80)†
DM, IN/TN (%) 4/16 (25) 1/6 (17) 3/10 (30)
eGFR, mL/min/1.73 m2 55.6 ± 11.6 56.4 ± 12.7 52.1 ± 10.0
Ht, % 39.6 ± 3.3 39.5 ± 2.7 39.7 ± 3.8
Plt, 104/μL 19.7 ± 6.1 21.7 ± 6.1 17.2 ± 3.7
Medication
  ARB/ACE-I, IN/TN (%) 11/16 (69) 4/6 (67) 7/10 (70)
  Beta blocker, IN/TN (%) 7/16 (44) 3/6 (50) 4/10 (40)
  Diuretic, IN/TN (%) 4/16 (25) 2/6 (33) 2/10 (20)
  Statin, IN/TN (%) 9/16 (56) 2/6 (33) 7/10 (70)
Continuous variables are expressed as mean ± SD. IN/TN: incidence number/total number of 
subjects; BMI: body mass index; HTN: hypertension; DL: dyslipidemia; DM: diabetes mellitus; AF: 
atrial fibrillation; eGFR: estimated glomerular filtration rate; Ht: hematocrit; Plt: platelet counts; 
ARB/ACE-I: angiotensin II receptor blocker/angiotensin converting enzyme inhibitor. †P < 0.05 vs. 
rivaroxaban group.
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effect of blood rheology [15, 16]. Thus, we measured the hem-
atocrit and platelet counts for all the patients, and examined the 
associations between these parameters and T-TAS® measure-
ments. There were no differences in the hematocrit or platelet 
counts between the rivaroxaban and apixaban groups (Table 
2). According to the correlation analysis, the hematocrit was 
not associated with either AR-AUC or PL-AUC at the trough 
(Fig. 5a, b). In contrast, the platelet count was moderately as-
sociated with AR-AUC at the trough (r = 0.57, P = 0.03) (Fig. 
5c), whereas it was not significantly correlated with PL-AUC 
(r = 0.48, P = 0.08) (Fig. 5d).
Discussion
In the present study, we determined whether T-TAS® could be 
a useful tool for monitoring the anticoagulant effects of rivar-
oxaban and apixaban under various conditions. Our main find-
ings were as follows: 1) The T-TAS® could detect anticoagu-
lant capacities in samples treated in vitro with rivaroxaban or 
apixaban. 2) The enhancements of the anticoagulant capacities 
of rivaroxaban and apixaban from concentrations at the trough 
to peak were successfully monitored by the T-TAS® using ex 
vivo samples. 3) In the T-TAS® analysis, the antithrombotic 
capacity of FXa inhibitors at the peak dose was strongly linked 
to that at the trough.
Recent clinical trials have successfully demonstrated that 
the T-TAS® could be used to monitor platelets and the co-
agulation system under various conditions [17-19]. One of 
the advantages of the T-TAS® assay is that it enables simple 
point-of-care tests with short turnaround times. The process 
of thrombus formation is monitored quantitatively in real 
time and measurements are fully computed for assessment. 
Another advantage is that flow-chamber testing under vari-
ous shear conditions with whole blood samples may be more 
physiological and comprehensive, since this simultaneously 
evaluates both cellular and soluble elements of hemostasis. 
On the other hand, the T-TAS® is an indirect assay, which is 
not specific for FXa concentrations, since the rate of throm-
bus formation might be affected by patient characteristics 
other than the dosage of FXa inhibitors. For example, dia-
betic patients show high platelet reactivity and enhanced co-
agulation regardless of the administration of antithrombotic 
agents [20]. Therefore, in this study, whole blood samples 
from healthy volunteers were first used in a T-TAS® analy-
sis to validate the anticoagulant effects of drugs. At clinically 
relevant peak concentrations, the addition of rivaroxaban to 
whole blood samples significantly decreased athero-throm-
bogenicity as indicated by AR-AUC. In vitro treatment with 
apixaban also decreased AR-AUC. As expected, AR-AUC 
levels in the two groups were similar, which confirmed that 
the T-TAS® is useful for monitoring the anticoagulant effects 
of rivaroxaban and apixaban. Moreover, the other AR pa-
rameters, AR-T10 and AR-T80, were also similar between the 
rivaroxaban and the apixaban groups. These results suggest 
that rivaroxaban and apixaban have identical antithrombotic 
properties throughout thrombus formation under the condi-
tion of platelets and coagulation-fibrinolysis factors. Simi-
larly, with the use of blood samples from patients given rivar-
oxaban or apixaban, our ex vivo experiments demonstrated 
that AR-AUC levels were significantly decreased from the 
trough to peak in both groups. Along with AR-AUC levels, 
AR-T10 and AR-T80 were prolonged in both the rivaroxaban 
and apixaban groups in a concentration-dependent manner. 
In contrast to the in vitro experiment, the rivaroxaban group 
Table 3.  Changes in T-TAS® Parameters, PT-INR and APTT 
at Trough and Peak in Blood in the Rivaroxaban and Apixaban 
Groups
Rivaroxaban (n = 6) Apixaban (n = 10)
Trough Peak Trough Peak
AR-T10 (min) 9.2 ± 2.9 12.3 ± 2.3 11.9 ± 2.5 15.5 ± 3.2*
AR-T80 (min) 13.7 ± 3.2 18.3 ± 3.5* 18.3 ± 3.1† 22.0 ± 3.3*
PL-T10(min) 2.4 ± 0.7 2.4 ± 1.5 2.9 ± 1.3 3.5 ± 1.0
PL-T60 (min) 6.7 ± 1.3 6.2 ± 0.8 8.3 ± 0.8 8.0 ± 0.3
PT-INR 1.2 ± 0.2 1.3 ± 0.2 1.1 ± 0.1 1.2 ± 0.1
APTT (s) 34.4 ± 5.3 40.7 ± 14.3 31.4 ± 2.3 31.9 ± 2.8
Continuous variables are expressed as mean ± SD. *P < 0.05 vs. 
trough, †P < 0.05 vs. rivaroxaban group.
Figure 2. Antithrombotic capacities (AR-AUC (a) and PL-AUC (b)) at 
trough and peak in blood from patients. †P < 0.05 vs. rivaroxaban at 
trough. *P < 0.05 vs. trough. 
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Figure 3. Associations between AR-AUC and common coagulant tests in all patients. 
Figure 4. Associations between T-TAS® parameters at trough and peak in all patients. 
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at the trough had less anticoagulant capacity, as indicated by 
higher AR-AUC levels and shorter AR-T80, than the apixaban 
group at the trough. According to pharmacokinetic and phar-
macodynamic studies, 10 mg rivaroxaban taken orally once 
daily had a higher peak to trough drug concentration ratio in 
a steady state, compared to 2.5 mg apixaban taken twice daily 
[21-23]. Therefore, the decreased blood concentration of ri-
varoxaban at the trough might result in lower AR-AUC levels 
due to the different dose regimens in the present study. Based 
on the findings from our in vitro and ex vivo experiments, we 
believe that T-TAS® parameters obtained using the AR-chip 
under a constant shear flow of 600/s are useful for accurate 
quantitative monitoring of the anticoagulant effects of rivar-
oxaban and apixaban.
The antiplatelet effects of FXa inhibitors have recently 
become a new therapeutic target in patients with cardiovascu-
lar disease. The ATLAS ACS 2-TIMI 51 study demonstrated 
that the addition of rivaroxaban reduced cardiovascular events 
and mortality in patients with recent acute coronary syndrome 
[24]. Along with T-TAS® monitoring with an AR-chip, we 
also sought to evaluate pure platelet thrombus formation us-
ing a PL-chip. For PL analysis, blood samples were applied 
to PL-chips under a shear flow of 1,000/s, which simulates 
the shear conditions at the arterial wall. As shown in Figure 
1b, neither rivaroxaban nor apixaban supplementation in vitro 
promoted platelet thrombus formation in whole blood sam-
ples from healthy subjects. Similarly, data from the ex vivo 
experiment did not show that the doses of the FXa inhibitors 
influenced platelets (Fig. 2b). In both the rivaroxaban and 
apixaban groups, no differences were observed between PL-
AUC at the trough and PL-AUC at the peak. Although the 
rivaroxaban group had less athero-thrombogenicity at the 
trough in the AR-chip analysis, this group had a similar ca-
pacity for platelet thrombus formation at any time point in 
PL-chip analysis, as compared to the apixaban group. We 
previously reported that blood samples from patients who 
were taking NOACs, including dabigatran, rivaroxaban and 
apixaban, had significantly lower PL-AUC levels at trough 
than control blood from patients who were not receiving any 
anticoagulant [11]. Taken together, PL analysis by T-TAS® for 
patients was influenced by NOACs administration, but it was 
not suitable for the quantitative assessment of platelet func-
tion of NOACs.
It can be difficult to quantify NOAC activity by a common 
coagulant test, such as PT-INR or APTT, because PT-INR and 
APTT may be within their normal ranges at trough drug levels 
[25]. Nevertheless, several studies have reported that FXa in-
hibitors prolonged PT linearly at high concentrations, and this 
effect was modestly correlated with anti-FXa activity [19, 26]. 
In our population, the PT-INR and APTT levels were similar 
in the rivaroxaban and apixaban groups at all of the time points 
tested. The PT and APTT from the trough to peak were also not 
prolonged, which indicated that PT-INR and APTT were not 
sensitive even at the clinically peak concentrations of rivar-
oxaban and apixaban. In addition, AR-AUC did not show any 
correlations with PT-INR or APTT at the trough or peak. Thus, 
T-TAS® monitoring of anticoagulant capacity is independent 
of PT-INR and APTT, and T-TAS® measurement may play a 
different role in anticoagulant monitoring than an anti-FXa ac-
tivity assay.
A previous report demonstrated that blood constituents, 
such as the hematocrit and platelet counts, might contribute 
Figure 5. Associations between T-TAS® parameters and complete blood count tests in all patients. 
Articles © The authors   |   Journal compilation © J Clin Med Res and Elmer Press Inc™   |   www.jocmr.org906
Effects of Rivaroxaban and Apixaban J Clin Med Res. 2016;8(12):899-907
to the measurements in the T-TAS® [27]. In our ex vivo analy-
sis, the hematocrit and platelet counts in the rivaroxaban group 
were comparable to those in the apixaban group. A correlation 
analysis showed that the hematocrit was not related to any T-
TAS® parameters including AR-AUC and PL-AUC, whereas 
platelet counts were significantly associated with AR-AUC 
(but not with PL-AUC). The strength of the correlation be-
tween AR-AUC at the trough and platelet counts was moder-
ate (r = 0.57, P = 0.03), which was consistent with the results 
in a previous report from another group using samples from 
healthy individuals (r = 0.51, in ref. 31). Based on these data, 
while platelet counts may confound T-TAS® measurements 
with an AR-chip, this interaction may not be influenced by dis-
orders or NOAC medications.
Finally, do we need serial measurements with the T-TAS® 
to monitor the antithrombotic effects of FXa inhibitors? Also, 
what AR-parameters would provide the greatest insight into 
these effects? As shown in Figure 2, all AR parameters at the 
trough, AR-AUC, AR-T10 and AR-T80, were strongly corre-
lated with those at the peak (r = 0.79, 0.72 and 0.81, respec-
tively). PL-AUC at the trough was also correlated to that at the 
peak, albeit this may not be suitable for quantification. Thus, 
we believe that the inter-individual variability in the dose-re-
sponse relationship between rivaroxaban or apixaban and an-
ticoagulant capacity is not high in the steady state, and hence, 
serial T-TAS® measurements are not necessary. The endpoints 
of our T-TAS® analysis with an AR-chip included AR-AUC, 
AR-T10 and AR-T80, which corresponded to the overall throm-
bogenicity, the time to the onset of thrombus formation and 
the time to capillary thrombus occlusion. In our in vitro and 
ex vivo experiments, treatment with rivaroxaban or apixaban 
significantly changed all of the AR parameters, and the mean 
rates of change from the trough to peak were similar among 
AR-AUC, AR-T10 and AR-T80. In addition to AR-AUC, AR-
T10 and AR-T80 at the trough strongly correlated with the val-
ues at the peak, and the strength of the correlation was identi-
cal among these AR parameters (Fig. 5). Thus, we consider 
that all AR parameters are useful for monitoring the effects of 
rivaroxaban and apixaban. None of these parameters appears 
to offer any special advantage for clinical use. However, the 
measurement of AR-T10 alone may be acceptable for rapid 
testing in an emergency setting.
This study has several limitations. First, the study was 
cross-sectional and included a relatively small number of pa-
tients. Second, many of the patients had HTN, DM or DL, 
which may have influenced the measurements, although the 
patients did not receive any medications that should have af-
fected thrombus formation, except for rivaroxaban or apixa-
ban. Third, plasma concentrations of NOACs were not meas-
ured. Further studies will be needed to clarify the effects of 
these limitations.
Conclusion
The T-TAS® with an AR-chip was a useful tool for monitoring 
the anticoagulant effects of FXa inhibitors regardless of the 
patient characteristics, and may provide accurate quantitative 
results.
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